{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:40:42Z","timestamp":1792795242253,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajt.2026.04.018","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:37:53Z","timestamp":1777073873000},"page":"1864-1878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-6128","authenticated-orcid":false,"given":"Arjang","family":"Djamali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-912X","authenticated-orcid":false,"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-3680","authenticated-orcid":false,"given":"Roslyn B.","family":"Mannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0527-898X","authenticated-orcid":false,"given":"Steve","family":"Chadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1961-0477","authenticated-orcid":false,"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-6947","authenticated-orcid":false,"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8534-8846","authenticated-orcid":false,"given":"Gabriele","family":"Schultz-Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6774-5906","authenticated-orcid":false,"given":"Gabriela","family":"Alperovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6278-6884","authenticated-orcid":false,"given":"Ralph","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2036-7910","authenticated-orcid":false,"given":"Laurie A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1674-1423","authenticated-orcid":false,"given":"Tobias","family":"Rogosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9346-7708","authenticated-orcid":false,"given":"Isabelle","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-1381","authenticated-orcid":false,"given":"Charles","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-5942","authenticated-orcid":false,"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7222-3356","authenticated-orcid":false,"given":"Michael","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7393-7799","authenticated-orcid":false,"given":"Peter W.","family":"Nickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajt.2026.04.018_bib1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.humimm.2016.01.018","article-title":"Current outcomes of chronic active antibody mediated rejection \u2013 a large single center retrospective review using the updated BANFF 2013 criteria","volume":"77","author":"Redfield","year":"2016","journal-title":"Hum Immunol"},{"issue":"5","key":"10.1016\/j.ajt.2026.04.018_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"issue":"suppl 4","key":"10.1016\/j.ajt.2026.04.018_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ajt.17210","article-title":"Rationale for the IMAGINE study for chronic active antibody-mediated rejection (caAMR) in kidney transplantation","volume":"22","author":"Nickerson","year":"2022","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2026.04.018_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/TP.0000000000004822","article-title":"Chronic active antibody-mediated rejection: opportunity to determine the role of interleukin-6 blockade","volume":"108","author":"Berger","year":"2024","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.ajt.2026.04.018_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1034\/j.1600-6143.2002.21015.x","article-title":"Death after graft loss: an important late study endpoint in kidney transplantation","volume":"2","author":"Kaplan","year":"2002","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2026.04.018_bib8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/j.1600-6143.2005.00921.x","article-title":"Patient survival following renal transplant failure in Canada","volume":"5","author":"Knoll","year":"2005","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2026.04.018_bib9","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1111\/ajt.16463","article-title":"Long-term kidney transplant graft survival\u2014making progress when most needed","volume":"21","author":"Poggio","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2026.04.018_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2026.04.018_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/TP.0000000000005187","article-title":"Chronic rejection after kidney transplantation","volume":"109","author":"Diebold","year":"2024","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":"Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure","volume":"90","author":"Gaston","year":"2010","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.ajt.2026.04.018_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2015.02.004","article-title":"The perfect storm: HLA antibodies, complement, Fc\u03b3Rs, and endothelium in transplant rejection","volume":"21","author":"Thomas","year":"2015","journal-title":"Trends Mol Med"},{"issue":"6","key":"10.1016\/j.ajt.2026.04.018_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001638","article-title":"Absence of IL-6 receptor blockade effect on the outcomes of transplant glomerulopathy in the absence of anti-HLA donor-specific antibodies","volume":"10","author":"Mella","year":"2024","journal-title":"Transplant Direct"},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/TP.0000000000001452","article-title":"Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade","volume":"101","author":"Jordan","year":"2017","journal-title":"Transplantation"},{"issue":"suppl 4","key":"10.1016\/j.ajt.2026.04.018_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.17207","article-title":"Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts","volume":"22","author":"Jordan","year":"2022","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2026.04.018_bib17","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1097\/00007890-199705270-00023","article-title":"Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction","volume":"63","author":"Casiraghi","year":"1997","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ajt.2026.04.018_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1432-2277.1993.tb00757.x","article-title":"Interleukin-6 and neopterin in renal transplant recipients: a longitudinal study","volume":"6","author":"Raasveld","year":"1993","journal-title":"Transpl Int"},{"issue":"9","key":"10.1016\/j.ajt.2026.04.018_bib19","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti\u2013interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2026.04.018_bib20","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1111\/ajt.16459","article-title":"Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial","volume":"21","author":"Chandran","year":"2021","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2026.04.018_bib21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/TP.0000000000002895","article-title":"Impact of tocilizumab (anti\u2013IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection","volume":"104","author":"Shin","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ajt.2026.04.018_bib22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of anti\u2013IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2026.04.018_bib23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ekir.2022.01.1074","article-title":"Evaluation of clazakizumab (anti\u2013interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts","volume":"7","author":"Jordan","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.ajt.2026.04.018_bib24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ajt.16926","article-title":"Clazakizumab for desensitization in highly sensitized patients awaiting transplantation","volume":"22","author":"Vo","year":"2022","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1186\/s13063-022-06897-3","article-title":"Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: phase 3 IMAGINE study rationale and design","volume":"23","author":"Nickerson","year":"2022","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.ajt.2026.04.018_bib26","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ajt.2026.04.018_bib27","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti\u2013interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ajt.2026.04.018_bib28","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"Weinblatt","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ajt.2026.04.018_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/TP.0000000000004285","article-title":"Anti-interleukin-6 antibody clazakizumab in antibody-mediated renal allograft rejection: accumulation of antibody-neutralized interleukin-6 without signs of proinflammatory rebound phenomena","volume":"107","author":"Borski","year":"2023","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ajt.2026.04.018_bib30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/TP.0000000000003274","article-title":"Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation","volume":"105","author":"Irish","year":"2021","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology","volume":"17","author":"Loupy","year":"2017","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2026.04.018_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ajt.2026.04.018_bib34","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1016\/j.ekir.2025.08.027","article-title":"The effects of clazakizumab on peripheral blood and kidney transcriptomes in patients with late antibody-mediated rejection","volume":"10","author":"Zhang","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.ajkd.2019.07.019","article-title":"Change in albuminuria and estimated GFR as end points for clinical trials in early stages of CKD: a perspective from European regulators","volume":"75","author":"Holtkamp","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.ajt.2026.04.018_bib36","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"10.1016\/j.ajt.2026.04.018_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13063-024-08020-0","article-title":"Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)","volume":"25","author":"Streichart","year":"2024","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.ajt.2026.04.018_bib40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajt.2026.04.018_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2025.04.023","article-title":"A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients","volume":"108","author":"Mulley","year":"2025","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.ajt.2026.04.018_bib42","article-title":"TRANSCEND: a phase 3 trial of the anti-CD38 antibody felzartamab in kidney transplant recipients with late antibody-mediated rejection","volume":"25","author":"Bohmig","year":"2025","journal-title":"Am J Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526002261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526002261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:05:57Z","timestamp":1785179157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613526002261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1600613526002261"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2026.04.018","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2026.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}